GLP-1R Agonist Antibodies for Weight Management, Primed for Clinical Development
Antibodies with best-in-class potential for addressing the growing need in obesity and diabetes.
Obesity is a global medical concern and its prevalence has nearly tripled in the last 50 years. Worldwide, 39% of adults (>1.9B) are overweight, while 13% of adults (650M) are obese. Effective therapeutic options are needed, as obesity puts patients at a higher risk of developing insulin resistance and serious comorbidities:
• Non-alcoholic steatohepatitis (NASH)